<DOC>
	<DOCNO>NCT03053024</DOCNO>
	<brief_summary>The purpose study ( retrospective prospective ) describe participant disease characteristic treatment pattern Bortezomib treat mantle cell lymphoma ( MCL ) participant China .</brief_summary>
	<brief_title>Study Bortezomib ( BTZ ) Treatment Mantle Cell Lymphoma ( MCL ) Chinese Participants</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Participants hospitalize MCL January 1st 2009 . Biopsy proven MCL evidence histology either immunohistochemistry ( IHC ) ( 11,14 ) translocation Retrospective group : Participants finish BTZ treatment study initiation judge participate site physician If participant n't accessible oral write informed consent , ICF waive approve IRB Prospective group : Participants BTZ time study initiation start BTZ study initiation Participants document diagnosis cancer prior presence diagnosis MCL Participants enrol interventional clinical trial BTZ drug MCL Prospective group : Participants contraindication list prescribe information BTZ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>